Zynlonta Patient - r/r DLBCL Treatment | ZYNLONTA® …
ZYNLONTA ® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer. It is not known if ZYNLONTA ® is safe and effective in children.
R/R DLBCL Treatment | ZYNLONTA® (loncastuximab tesirine-lpyl) …
2022年4月1日 · ZYNLONTA ® is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
Zynlonta: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年8月22日 · Zynlonta is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer. It is not known if this medicine is safe and effective in children.
Loncastuximab tesirine - Wikipedia
Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. [1][2] It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. [1]
ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more …
Zynlonta | European Medicines Agency (EMA)
2023年1月26日 · In patients with B-cell lymphoma, B-cells (a type of white blood cell) have become cancerous. The of Zynlonta, loncastuximab tesirine, is made up of a monoclonal antibody (a type of protein) combined with a cytotoxin (a substance that kills cells) called SG3199.
Dosing | ZYNLONTA® (loncastuximab tesirine-lpyl) HCP Site
ZYNLONTA ® is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from …
FAQs | ZYNLONTA® (loncastuximab tesirine-lpyl) Patient Site
What is ZYNLONTA ®? ZYNLONTA ® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer. It is not known if ZYNLONTA ® is safe and effective in children.
DailyMed - ZYNLONTA- loncastuximab tesirine injection, powder ...
2024年7月12日 · ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma ... 2.1 Recommended Dosage - ZYNLONTA as an intravenous infusion administered over 30 minutes on Day 1 of each cycle (every 3 weeks).
FDA grants accelerated approval to loncastuximab tesirine-lpyl for ...
On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and …